Literature DB >> 21787836

Activins and activin antagonists in the prostate and prostate cancer.

Elspeth Gold1, Gail Risbridger.   

Abstract

Activins are members of the TGF-β super-family. There are 4 mammalian activin subunits (β(A), β(B), β(C) and β(E)) that combine to form functional proteins. The role of activin A (β(A)β(A)) is well characterized and known to be a potent growth and differentiation factor. Two of the activin subunits (β(C) and β(E)) were discovered more recently and little is known about their biological functions. In this review the evidence that activin-β(C) is a significant regulator of activin A bioactivity is presented and discussed. It is concluded that activin-β(C), like other antagonists of activin A, is an important growth regulator in prostate health and disease.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21787836     DOI: 10.1016/j.mce.2011.07.005

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  14 in total

1.  Activin A expression in esophageal carcinoma and its association with tumor aggressiveness and differentiation.

Authors:  Zhenhua Wang; Ning Zhang; Ruifeng Song; Ruitai Fan; Liuqin Yang; Liping Wu
Journal:  Oncol Lett       Date:  2015-05-20       Impact factor: 2.967

2.  Activin A induces apoptosis of mouse myeloma cells via the mitochondrial pathway.

Authors:  Yuanyi Zhang; Yan Qi; Yang Zhao; Hongyan Sun; Jingyan Ge; Zhonghui Liu
Journal:  Oncol Lett       Date:  2017-12-11       Impact factor: 2.967

3.  Over-Expression of Activin-βC Is Associated with Murine and Human Prostate Disease.

Authors:  Edward C Ottley; Karen L Reader; Kailun Lee; Francesco E Marino; Helen D Nicholson; Gail P Risbridger; Elspeth Gold
Journal:  Horm Cancer       Date:  2017-01-23       Impact factor: 3.869

Review 4.  Clinical and Therapeutic Implications of Follistatin in Solid Tumours.

Authors:  Lei Shi; Jeyna Resaul; Sioned Owen; Lin Ye; Wen G Jiang
Journal:  Cancer Genomics Proteomics       Date:  2016 11-12       Impact factor: 4.069

Review 5.  Follistatin as potential therapeutic target in prostate cancer.

Authors:  Maria Vittoria Sepporta; Francesca Maria Tumminello; Carla Flandina; Marilena Crescimanno; Marco Giammanco; Maurizio La Guardia; Danila di Majo; Gaetano Leto
Journal:  Target Oncol       Date:  2013-03-01       Impact factor: 4.493

6.  Low miR-143/miR-145 Cluster Levels Induce Activin A Overexpression in Oral Squamous Cell Carcinomas, Which Contributes to Poor Prognosis.

Authors:  Andreia Bufalino; Nilva K Cervigne; Carine Ervolino de Oliveira; Felipe Paiva Fonseca; Priscila Campioni Rodrigues; Carolina Carneiro Soares Macedo; Lays Martin Sobral; Marcia Costa Miguel; Marcio Ajudarte Lopes; Adriana Franco Paes Leme; Daniel W Lambert; Tuula A Salo; Luiz Paulo Kowalski; Edgard Graner; Ricardo D Coletta
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

7.  Activins and their related proteins in colon carcinogenesis: insights from early and advanced azoxymethane rat models of colon cancer.

Authors:  Bassem Refaat; Adel Galal El-Shemi; Amr Mohamed Mohamed; Osama Adnan Kensara; Jawwad Ahmad; Shakir Idris
Journal:  BMC Cancer       Date:  2016-11-11       Impact factor: 4.430

8.  A NF-ĸB-Activin A signaling axis enhances prostate cancer metastasis.

Authors:  Lanpeng Chen; Marta De Menna; Arwin Groenewoud; George N Thalmann; Marianna Kruithof-de Julio; B Ewa Snaar-Jagalska
Journal:  Oncogene       Date:  2019-11-18       Impact factor: 9.867

9.  Expression profiling of prostate cancer tissue delineates genes associated with recurrence after prostatectomy.

Authors:  Martin Mørck Mortensen; Søren Høyer; Anne-Sophie Lynnerup; Torben Falck Ørntoft; Karina Dalsgaard Sørensen; Michael Borre; Lars Dyrskjøt
Journal:  Sci Rep       Date:  2015-11-02       Impact factor: 4.379

10.  Activin A programs the differentiation of human TFH cells.

Authors:  Michela Locci; Jennifer E Wu; Fortuna Arumemi; Zbigniew Mikulski; Carol Dahlberg; Andrew T Miller; Shane Crotty
Journal:  Nat Immunol       Date:  2016-07-04       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.